The company has been awarded funding through the program “Kompetensförstärkning i småföretag 2026.”

The funding will support a new project focused on the development planning of a green, dual-use nebulization technology designed for delivery of MucoLife’s lead therapeutic candidate, MLT-001. MLT-001 is a first-in-class inhaled therapy being developed to rapidly dissolve pathological mucus plugs in the lungs in both acute and chronic respiratory diseases, including COPD, cystic fibrosis, severe respiratory distress, and other muco-obstructive lung conditions.

The project aims to establish a comprehensive technical, regulatory, and commercial development roadmap for a sustainable nebulization platform optimized for both healthcare and emergency preparedness applications. The planned device is intended for use in hospitals, intensive care settings, home-care environments, and potential crisis-response scenarios.

Through the project, MucoLife Therapeutics will engage external expertise in nebulization technology, regulatory strategy, and sustainable product development to strengthen internal capabilities and reduce technical and regulatory risks ahead of future prototype development.

“We are very pleased to receive this support from Medtech4Health and Vinnova,” said Thaher Pelaseyed, CEO of MucoLife Therapeutics. “This project represents an important step toward enabling rapid and effective delivery of MLT-001 in both routine healthcare and emergency settings, while integrating sustainability and preparedness considerations from the outset.”